雌二醇辅助治疗育龄期女性精神分裂症的随机临床试验
这项在摩尔多瓦进行的8周随机安慰剂对照试验纳入200名19至46岁育龄期女性精神分裂症或分裂情感障碍患者,评估透皮雌二醇贴片辅助抗精神病药治疗的效果。
要点
- 透皮雌二醇贴片辅助治疗可显著改善育龄期女性精神分裂症阳性症状。
- 事后分析提示获益几乎仅见于38岁以上参与者,年轻参与者未见获益。
- 雌二醇组乳房胀痛和体重增加更常见。
核心结论
- 透皮雌二醇辅助抗精神病药治疗对育龄期女性精神分裂症患者的PANSS阳性子量表有统计学显著改善。
- 事后异质性分析提示该效应几乎完全见于38岁以上参与者,年轻参与者未获益。
研究设计与样本
- 纳入200名19至46岁绝经前女性,符合DSM-5精神分裂症或分裂情感障碍诊断。
- 干预为每周更换两次的200-μg雌二醇贴片或安慰剂贴片,附加于抗精神病药治疗。
- 主要结局为PANSS阳性子量表,按意向治疗以重复测量混合模型分析。
主要发现
- 雌二醇组和安慰剂组各100人,两组基线中位年龄均为38岁。
- 两组基线PANSS阳性子量表平均分合计为19.6;第8周安慰剂组平均14.4,雌二醇组平均13.4。
临床怎么用
- 对于育龄期女性精神分裂症患者,可考虑在抗精神病药基础上加用透皮雌二醇贴片以改善阳性症状。
- 需关注乳房胀痛和体重增加等不良反应。
- 38岁以上女性可能更可能从雌二醇辅助治疗中获益,年轻女性获益证据不足。
局限性
- 效应几乎完全见于38岁以上参与者的事后异质性分析结果需谨慎解读。
- 研究在摩尔多瓦进行,结果外推需考虑人群差异。
- 结论应结合女性与男性精神分裂症自然病程差异的背景看待。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Several lines of evidence suggest that estradiol influences the course of schizophrenia, and a previous randomized controlled trial demonstrated that transdermal estradiol improved symptoms in female patients of childbearing age. However, many initial positive findings in schizophrenia research are not later replicated. OBJECTIVE: To independently replicate the results of the effect of estradiol on schizophrenia in women of childbearing age. DESIGN, SETTING, AND PARTICIPANTS: An 8-week randomized, placebo-controlled trial performed in the Republic of Moldova between December 4, 2015, and July 29, 2016, among 200 premenopausal women aged 19 to 46 years with schizophrenia or schizoaffective disorder as defined by the DSM-5. INTERVENTION: Patients were randomized to receive a 200-μg estradiol patch or placebo patch changed twice a week added to their antipsychotic treatment. MAIN OUTCOMES AND MEASURES: The primary outcome was the positive subscale of the Positive and Negative Syndrome Scale (PANSS; lower scores indicated fewer symptoms and higher scores indicated more symptoms), analyzed with mixed models for repeated measures on an intention-to-treat basis. RESULTS: A total of 100 women (median age, 38 years; interquartile range, 34-42 years) were randomized to receive an estradiol patch and 100 women (median age, 38 years; interquartile range, 31-41 years) were randomized to receive a placebo patch; the median age at baseline for the entire group of 200 women was 38.0 years (range, 19.5-46.0 years). At baseline, the mean positive PANSS score was 19.6 for both groups combined; at week 8, the mean positive PANSS score was 14.4 in the placebo group and 13.4 in the estradiol group. Compared with placebo, participants receiving add-on estradiol patches had statistically significant improvements in the primary outcome measure, PANSS positive subscale points (-0.94; 95% CI, -1.64 to -0.24; P = .008; effect size = 0.38). Post hoc heterogeneity analyses found that this effect occurred almost entirely in 100 participants older than 38.0 years (46 in placebo group vs 54 in estradiol group; difference, -1.98 points on the PANSS positive subscale; 95% CI, -2.94 to -1.02; P < .001). Younger participants did not benefit from estradiol (difference, 0.08 points on the PANSS positive subscale; 95% CI, -0.91 to 1.07; P = .87). Breast tenderness was more common in the estradiol group (n = 15) than in the placebo group (n = 1) as was weight gain (14 in estradiol group vs 1 in placebo group). CONCLUSIONS AND RELEVANCE: The results independently replicate the finding that transdermal estradiol is an effective add-on treatment for women of childbearing age with schizophrenia and extend it, finding improvements in negative symptoms and finding that the effect could be specific to those older than 38 years. The results should be viewed in the context of the differences in the natural course of schizophrenia between females and males. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03848234.
引用
- Weiser M, Levi L, Zamora D, et al. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. JAMA Psychiatry. 2019. PMID: 31365044. doi:10.1001/jamapsychiatry.2019.1842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。